This brief examines the implications of rising prescriptions for costly GLP-1 drugs for state Medicaid programs as more states consider covering the drugs for weight loss. It examines recent trends in Medicaid prescriptions and gross spending on GLP-1s, and explores the potential implications of expanding coverage obesity drugs for Medicaid programs.| KFF
This analysis of survey data finds that over 40% of adults under 65 with private insurance could be indicated for a GLP-1 drug though relatively few have a claim, suggesting that a much smaller share seeks treatment through healthcare providers.| Peterson-KFF Health System Tracker
Drugmaker Eli Lilly is hoping tirzepatide, sold as Mounjaro and Zepbound for diabetes and weight loss, will become the first drug approved to treat sleep apnea, which it says affects some 80 million Americans, many of whom go undiagnosed and untreated.| Forbes
Health insurers submit rate filings annually to state regulators detailing expectations and rate changes for Affordable Care Act (ACA)-regulated health plans for the coming year. A relatively small, but growing, share of the population is enrolled in these plans (compared to the number in employer plans). However, these filings are generally more detailed and publicly […]| Peterson-KFF Health System Tracker
